Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- About
Maze Therapeutics, Inc. Common Stock (MAZE)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/14/2025: MAZE (3-star) is a STRONG-BUY. BUY since 25 days. Simulated Profits (77.90%). Updated daily EoD!
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit 56.18% | Avg. Invested days 21 | Today’s Advisory Regular Buy |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 10/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 525.32M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta - | 52 Weeks Range 6.71 - 17.00 | Updated Date 05/17/2025 |
52 Weeks Range 6.71 - 17.00 | Updated Date 05/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.42 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 32.97% | Operating Margin (TTM) -969.16% |
Management Effectiveness
Return on Assets (TTM) - | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 454876736 | Price to Sales(TTM) 3.14 |
Enterprise Value 454876736 | Price to Sales(TTM) 3.14 | ||
Enterprise Value to Revenue 2.72 | Enterprise Value to EBITDA 6.71 | Shares Outstanding 43777000 | Shares Floating 9631077 |
Shares Outstanding 43777000 | Shares Floating 9631077 | ||
Percent Insiders 11.49 | Percent Institutions 56.82 |
Upturn AI SWOT
Maze Therapeutics, Inc. Common Stock
Company Overview
History and Background
Maze Therapeutics, Inc. is a biopharmaceutical company founded in 2019, focused on developing new medicines that target genetic modifiers to treat a wide range of diseases.
Core Business Areas
- Precision Medicines: Development of targeted therapies based on genetic insights to treat diseases with clear genetic drivers.
- Drug Discovery Platform: Utilizing advanced data science and genomics to identify and validate novel drug targets.
Leadership and Structure
Jason Coloma, Ph.D., is the Chief Executive Officer. The company has a scientific advisory board comprising experts in genetics and drug development. The organizational structure includes research, development, and business operations teams.
Top Products and Market Share
Key Offerings
- MZE001 (Glycogen Storage Disease Type Ia (GSDIa)): A potential treatment for GSDIa, an inherited metabolic disorder. Currently in clinical trials. Market share is currently 0% as it is not yet approved. Competitors include Ultragenyx Pharmaceutical (RARE) (gene therapy focused) and companies developing dietary management strategies.
- Other Pipeline Programs: Developing treatments for other genetically defined diseases. Details on specific programs and market share are not yet publicly available. Competitors vary depending on the target disease.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high research and development costs, stringent regulatory requirements, and significant competition. The market for precision medicine is rapidly growing.
Positioning
Maze Therapeutics is positioned as a leader in leveraging genetic modifiers for drug discovery and development. Its competitive advantage lies in its proprietary platform and focus on genetically defined diseases.
Total Addressable Market (TAM)
The TAM for genetic disease therapies is estimated to be in the tens of billions of dollars. Maze Therapeutics aims to capture a significant portion of this market through its pipeline of novel treatments.
Upturn SWOT Analysis
Strengths
- Proprietary drug discovery platform
- Strong scientific team
- Focus on genetically defined diseases
- Pipeline of novel drug candidates
Weaknesses
- Early-stage company with no approved products
- High R&D costs
- Dependence on clinical trial success
- Limited revenue streams
Opportunities
- Expanding pipeline through new drug discovery
- Partnering with larger pharmaceutical companies
- Advancing clinical programs
- Securing regulatory approvals
Threats
- Clinical trial failures
- Competition from other biopharmaceutical companies
- Regulatory hurdles
- Intellectual property challenges
Competitors and Market Share
Key Competitors
- Ultragenyx Pharmaceutical (RARE)
- Vertex Pharmaceuticals (VRTX)
- BioMarin Pharmaceutical (BMRN)
Competitive Landscape
Maze Therapeutics competes with established biopharmaceutical companies with approved products and larger R&D budgets. Its advantage lies in its unique drug discovery platform and focus on genetic modifiers.
Growth Trajectory and Initiatives
Historical Growth: Growth is based on R&D progress and pipeline development.
Future Projections: Future growth is projected based on successful clinical trials, regulatory approvals, and commercialization of products.
Recent Initiatives: Advancing MZE001 in clinical trials, expanding drug discovery efforts, and securing funding.
Summary
Maze Therapeutics is an early-stage biopharmaceutical company focused on developing precision medicines for genetically defined diseases. The company's strength lies in its proprietary drug discovery platform and experienced team. However, it faces significant challenges due to high R&D costs and the inherent risks of clinical development. Success depends on advancing its pipeline and securing regulatory approvals.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
- ClinicalTrials.gov
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be based on independent research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Maze Therapeutics, Inc. Common Stock
Exchange NASDAQ | Headquaters South San Francisco, CA, United States | ||
IPO Launch date 2025-01-31 | CEO & Director Dr. Jason V. Coloma M.B.A., M.P.H., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 125 | Website https://www.mazetx.com |
Full time employees 125 | Website https://www.mazetx.com | ||
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of renal, cardiovascular, related metabolic diseases, and obesity in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor of the solute transporter SLC6A19, which is in phase I clinical trial for the treatment of chronic kidney disease. The company also offers MZE001, a clinical program for the treatment of Pompe disease. Maze Therapeutics, Inc. was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.